Can You Stop Dupilumab When Eczema Improves? What SOLO-CONTINUE Studied
DOCTOR’S NOTES · ECZEMA EVIDENCE
Clearer skin after treatment can raise an understandable question: is the medicine still needed? For dupilumab, a randomized maintenance trial investigated continued treatment, longer intervals and withdrawal in people who had already responded. Its findings help frame a discussion, but they are not instructions for changing an individual's injection schedule.
A study of responders, not everyone who started
SOLO-CONTINUE, published online in 2019 and in JAMA Dermatology in 2020, rerandomized 422 adult high responders from the earlier SOLO trials for another 36 weeks. Participants continued a frequent dupilumab regimen, received treatment at longer intervals or switched to placebo.
| Maintenance comparison | EASI-75 response maintained in the relevant analysis groups |
|---|---|
| Weekly or every-two-week dupilumab study group | 116/162 (71.6%) |
| Every-four-week study group | 49/84 (58.3%) |
| Every-eight-week study group | 45/82 (54.9%) |
| Placebo after initial response | 24/79 (30.4%) |
These EASI-75 results concern participants who had EASI-75 at maintenance baseline. That endpoint subset is smaller than the full 422-person randomized population. They are not the likelihood that any newly treated person will achieve the same outcome. The paper found the most consistent maintenance with the more frequent continued regimens.
What withdrawal does—and does not—show
A loss of response after switching to placebo suggests that improvement can depend on continued treatment. It does not prove that every person must receive one unchanged regimen forever. It also should not be retold as evidence of addiction: recurring disease activity and drug dependence are different claims.
The trial cannot predict exactly when a particular person's symptoms would return or identify a universal stopping point. Its selected adults, follow-up period and response definitions matter. A child who receives a different age- or weight-based regimen is not automatically represented by these adult maintenance results.
Discuss the reason for wanting a change
The next conversation may differ depending on whether the concern is a side effect, treatment burden, cost, access, pregnancy planning or a belief that clear skin means permanent cure. Tell the team which issue is driving the question. A missed supply delivery and a planned treatment review require different practical responses.
Bring information about itch, sleep, pain, skin involvement and accompanying topical therapy. A quiet clinic photograph may not capture what happens between visits. Ask how response is being judged and what evidence would support maintaining, modifying or reconsidering the plan.
Agree on instructions before an interruption
If an interruption is anticipated, contact the prescriber and dispensing team. Ask for the product-specific missed-dose instructions and a plan for worsening symptoms. Do not double doses or invent a longer interval from a trial table. If new symptoms are the reason for stopping, make sure they are assessed rather than simply disappearing from the medication history.
NIAMS describes individualized eczema management, including ongoing review of response and treatment. A practical plan should explain both the next step and when to request help.
Our initial dupilumab trial guide addresses starting-treatment evidence. The control and remission explanation helps distinguish a successful treatment period from a permanent cure.
Follow the related evidence
The topical application-frequency review addresses a different kind of treatment simplification. If safety concerns are driving a treatment question, the calcineurin-inhibitor evidence guide shows how research and a continuing warning can be discussed together; it does not establish dupilumab safety.
Dr. Arsy Moisturizer #003, 4 oz is a cosmetic moisturizer for hydration and moisture-barrier support. It does not treat, cure or prevent eczema. The medical studies discussed here did not test #003. Follow the current label and the prescriber’s directions for use with topical medicines. For infants, children, pregnancy or breastfeeding, discuss product suitability and the intended application area with the care team.
Educational content prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Individual diagnosis and treatment require a qualified clinician. The AI-created product image is an editorial illustration, not a patient photograph or clinical result. Cited researchers and organizations do not endorse Dr. Arsy products.